Real-World trial tests aggressive drug combo to fight blood cancer
NCT ID NCT07206810
Summary
This study followed 419 adults newly diagnosed with multiple myeloma, a blood cancer, to see how well a specific three-drug combination (VRD) works in real-world hospital practice. Patients received the drug regimen, and those eligible also underwent a stem cell transplant, followed by long-term maintenance therapy to keep the cancer in check. The goal was to control the disease and monitor how patients responded and survived over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.